AI Article Synopsis
- * A 56-year-old woman developed psoriatic alopecia and paradoxical psoriasis after starting adalimumab but improved after switching to certolizumab, with her condition assessed via trichoscopy and reflectance confocal microscopy.
- * Certolizumab is noted for having a lower risk of causing paradoxical reactions compared to other anti-TNF-α agents and is considered a safe, effective treatment option for managing psoriasis and psoriatic arthritis.
Article Abstract
Introduction: Psoriatic alopecia is considered a type of hair loss occurring in patients with psoriasis. Adalimumab is a fully humanized recombinant anti-TNF-alpha monoclonal antibody approved for treatment of psoriasis and psoriatic arthritis (PsA), rarely related to the occurrence of dermatological disorders.
Case Presentation: We report the case of a 56-year-old female with PsA developing psoriatic alopecia and paradoxical psoriasis induced by adalimumab and successfully treated switching to certolizumab, evaluating response at both thrichoscopy and in vivo reflectance confocal microscopy.
Discussion: Among anti-TNF-α agents, certolizumab is the least involved in the development of paradoxical reactions such as psoriatic alopecia and showed to be an effective and safe alternative therapeutic options to manage psoriasis and PsA minimizing the risk of paradoxical reactions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264901 | PMC |
| http://dx.doi.org/10.1159/000527985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!